Serum Cystatin C Levels in COPD: Potential Diagnostic Value and Relation Between Respiratory Functions

Overview

Journal J Med Biochem

Specialty Biochemistry

Date 2018 Dec 26

PMID 30584402

Citations 8

Authors

Selda Telo

Mutlu Kuluozturk

Figen Deveci

Gamze Kirkil

Onsel Oner

Dilara Kaman

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to determine the level of serum cystatin C (CysC) in patients with Chronic Obstructive Pulmonary Disease (COPD) during exacerbation and stable periods and to investigate its potential diagnostic value and the relationship between CysC levels and the pulmonary function test (PFT).

Methods: One hundred twenty-six patients with COPD (68 in stable periods, 58 during exacerbation periods) and 50 healthy subjects were included in the study. PFT, body mass index (BMI), white blood cell counts, C-reactive protein (CRP), serum urea and creatinine levels were evaluated in both groups of patients. CysC levels were measured in all participants.

Results: Serum CysC levels were statistically higher in both COPD groups than the control group (p<0.001 for both) although there was no statistically significant difference between COPD groups (p>0.05). CysC levels showed negative correlation with forced expiratory volume in 1 second (FEV) and a positive correlation with C-reactive protein (CRP) levels in patients with stable COPD. There was a positive correlation between serum CysC levels and serum urea, creatinine, CRP levels in patients with COPD exacerbation (r=0.333, p=0.011; r=0.260, p=0.049; r=0.414, p<0.01 respectively). When stable COPD and control groups were evaluated, serum CysC had an area under the curve (AUC) in the receiver operating characteristic (ROC) curve of 0.951 (0.909-0.994 95% CI: p<0.001).

Conclusions: Our results showed that CysC levels increased in both COPD groups. Increased CysC levels may be related with lung function decline and inflammation in COPD patients. In addition, CysC levels may be a potential indicator for the diagnosis of COPD.

Citing Articles

Association between Serum Cys C and PTB Cavitation.

Tan S, Wu D, Wu Y, Ren X, Liu J, Wei X Dis Markers. 2023; 2023:6465182.

PMID: 37091891 PMC: 10115526. DOI: 10.1155/2023/6465182.

Effect of propolis and N-acetylcysteine supplementation on lipoprotein subclasses distribution and paraoxonase 1 activity in subjects with acute respiratory infection.

Vekic J, Ivanisevic J, Zeljkovic A, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Mihajlovic M J Med Biochem. 2020; 39(4):467-473.

PMID: 33312063 PMC: 7710374. DOI: 10.5937/jomb0-24695.

Development of an Approach of High Sensitive Chemiluminescent Assay for Cystatin C Using a Nanoparticle Carrier.

Sun Y, Tao L, Ma Y, Yang S, Zhang X, Jin B Front Chem. 2020; 8:802.

PMID: 33134263 PMC: 7505105. DOI: 10.3389/fchem.2020.00802.

Serum Cystatin C and Coronavirus Disease 2019: A Potential Inflammatory Biomarker in Predicting Critical Illness and Mortality for Adult Patients.

Chen D, Sun W, Li J, Wei B, Liu W, Wang X Mediators Inflamm. 2020; 2020:3764515.

PMID: 33061826 PMC: 7545455. DOI: 10.1155/2020/3764515.

The association between cystatin C and COPD: a meta-analysis and systematic review.

Chai L, Feng W, Zhai C, Shi W, Wang J, Yan X BMC Pulm Med. 2020; 20(1):182.

PMID: 32586317 PMC: 7318461. DOI: 10.1186/s12890-020-01208-5.

References

Fliser D, Ritz E . Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001; 37(1):79-83. DOI: 10.1053/ajkd.2001.20628. View

Balta S, Demirkol S, Ay S, Cakar M, Sarlak H, Celik T . Serum cystatin-C levels correlate with endothelial dysfunction in patients with the metabolic syndrome. J Intern Med. 2013; 274(2):200-1. DOI: 10.1111/joim.12078. View

Takeyabu K, Betsuyaku T, Nishimura M, Yoshioka A, Tanino M, Miyamoto K . Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur Respir J. 1998; 12(5):1033-9. DOI: 10.1183/09031936.98.12051033. View

Randers E, Erlandsen E . Serum cystatin C as an endogenous marker of the renal function--a review. Clin Chem Lab Med. 1999; 37(4):389-95. DOI: 10.1515/CCLM.1999.064. View

Sarir H, Henricks P, van Houwelingen A, Nijkamp F, Folkerts G . Cells, mediators and Toll-like receptors in COPD. Eur J Pharmacol. 2008; 585(2-3):346-53. DOI: 10.1016/j.ejphar.2008.03.009. View

Quanjer P, Tammeling G, Cotes J, Pedersen O, Peslin R, Yernault J . Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16:5-40. View

Hu G, Wu Y, Zhou Y, Yu Y, Liang W, Ran P . Cystatin C as a Predictor of In-Hospital Mortality After Exacerbation of COPD. Respir Care. 2016; 61(7):950-7. DOI: 10.4187/respcare.04034. View

Lomas D . Does Protease-Antiprotease Imbalance Explain Chronic Obstructive Pulmonary Disease?. Ann Am Thorac Soc. 2016; 13 Suppl 2:S130-7. DOI: 10.1513/AnnalsATS.201504-196KV. View

Yoshizawa T, Okada K, Furuichi S, Ishiguro T, Yoshizawa A, Akahoshi T . Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int J Chron Obstruct Pulmon Dis. 2015; 10:1283-9. PMC: 4500615. DOI: 10.2147/COPD.S80673. View

10.

Colak A, Yilmaz C, Toprak B, Aktogu S . Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD. J Med Biochem. 2017; 36(2):122-126. PMC: 5471644. DOI: 10.1515/jomb-2017-0011. View

11.

Donaldson G, Seemungal T, Patel I, Bhowmik A, Wilkinson T, Hurst J . Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4):1995-2004. PMC: 7172405. DOI: 10.1378/chest.128.4.1995. View

12.

Shastri S, Katz R, Shlipak M, Kestenbaum B, Peralta C, Kramer H . Cystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2011; 57(6):832-40. PMC: 3090544. DOI: 10.1053/j.ajkd.2010.11.021. View

13.

Rintahaka J, Lietzen N, Ohman T, Nyman T, Matikainen S . Recognition of cytoplasmic RNA results in cathepsin-dependent inflammasome activation and apoptosis in human macrophages. J Immunol. 2011; 186(5):3085-92. DOI: 10.4049/jimmunol.1002051. View

14.

Lee Y, Chen S, Shyu L, Lee M, Wu T, Tsao S . Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin Chim Acta. 2012; 413(5-6):630-5. DOI: 10.1016/j.cca.2011.12.010. View

15.

Rokadia H, Agarwal S . Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES). Lung. 2012; 190(3):283-90. DOI: 10.1007/s00408-012-9374-z. View

16.

Zhang M, Li Y, Yang X, Shan H, Zhang Q, Ming Z . Serum Cystatin C as an Inflammatory Marker in Exacerbated and Convalescent COPD Patients. Inflammation. 2015; 39(2):625-31. DOI: 10.1007/s10753-015-0287-x. View

17.

Anthonisen N, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2):196-204. DOI: 10.7326/0003-4819-106-2-196. View

18.

Zhang Y, Zhu Y, Wu Y, Wang G, Xie X, Ke R . Serum cystatin C as a potential biomarker for the evaluation COPD. Int J Clin Exp Med. 2015; 7(12):5484-90. PMC: 4307506. View

19.

Chapman Jr H, Reilly Jr J, Yee R, Grubb A . Identification of cystatin C, a cysteine proteinase inhibitor, as a major secretory product of human alveolar macrophages in vitro. Am Rev Respir Dis. 1990; 141(3):698-705. DOI: 10.1164/ajrccm/141.3.698. View

20.

Al-Azzawi M, Ghoneim A, Elmadbouh I . Evaluation of Vitamin D, Vitamin D Binding Protein Gene Polymorphism with Oxidant - Antioxidant Profiles in Chronic Obstructive Pulmonary Disease. J Med Biochem. 2018; 36(4):331-340. PMC: 6294086. DOI: 10.1515/jomb-2017-0012. View